ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1563068
Prognostic Significance of Serum Galectin-3 in Predicting Cardiovascular Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents
Provisionally accepted
- Department of Internal Medicine, Cardiovascular Center and Cardiology Division, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea., Seoul, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Galectin-3 is a well-established biomarker on predictor of cardiovascular events in patients with heart failure. Its pathophysiologic association with inflammation, cell proliferation, and fibrogenesis may implicate serum galectin-3 as a predictor of clinical outcomes in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The aim of this study was to examine the prognostic value of the galectin-3 level in patients with CAD who underwent PCI with DES.A total of 939 patients undergoing successful PCI with DES were consecutively enrolled from January 2007 to December 2009. Serum galectin-3 level was measured, classified into two groups according to median galectin-3 level (9.52 ng/ml, interquartile range 7.31 to 12.81), and compared with the composite of all-cause mortality, nonfatal MI, and strokeMedian follow up duration was 997 days (interquartile range 766 to 1,264 days). High galectin-3 group had significantly higher incidence of all-cause mortality, cardiac mortality, and composite of all-cause mortality, nonfatal myocardial infarction (MI), and stroke. High galectin-3 was a significant independent predictor of composite of all-cause mortality, nonfatal MI, and stroke (adjusted hazard ratio 1.670, 95% confidence interval 1.014 to 2.751, p=0.044). Addition of serum galectin-3 level to the conventional clinical risk model improves the model discrimination (C-static=0.694 to 0.786, p for difference < 0.01) and reclassification (continuous net classification improvement (0.297, p<0.01), integrated discrimination improvement (0.064, p<0.01)).Our data suggest that serum galectin-3 is an independent predictor of cardiovascular events in patients undergoing PCI with DES.
Keywords: galectin-3, predictor, Coronary Artery Disease, Percutaneous Coronary Intervention, Drug-
Received: 19 Jan 2025; Accepted: 24 Jun 2025.
Copyright: © 2025 Choi and Seo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Suk Min Seo, Department of Internal Medicine, Cardiovascular Center and Cardiology Division, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea., Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.